Patents by Inventor Yvonne Saenger

Yvonne Saenger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Biomarker associated with risk of melanoma reoccurrence
    Patent number: 10626463
    Abstract: The present invention provides a method of predicting the risk of reoccurrence of melanoma in a patient from whom melanoma tissue was previously removed which comprises the following: a. obtaining a RNA-containing sample of the previously removed melanoma tissue containing RNA from the patient; b. treating the sample to determine from the RNA contained in the sample the level of expression of a plurality of preselected genes; and c. comparing the level of expression of each gene of the plurality of pre-selected genes to a predetermined reference level of expression for each such gene; wherein a higher level of expression of the plurality of pre-selected genes in the sample as compared with the predetermined reference level of expression of such genes indicates that the patient has a reduced risk of reoccurrence of melanoma.
    Type: Grant
    Filed: August 2, 2013
    Date of Patent: April 21, 2020
    Assignee: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
    Inventors: Yvonne Saenger, Shanthi Sivendran, Rui Chang, Analisa Difeo
  • BIOMARKER ASSOCIATED WITH RISK OF MELANOMA REOCCURRENCE
    Publication number: 20150218649
    Abstract: The present invention provides a method of predicting the risk of reoccurrence of melanoma in a patient from whom melanoma tissue was previously removed which comprises the following: a. obtaining a RNA-containing sample of the previously removed melanoma tissue containing RNA from the patient; b. treating the sample to determine from the RNA contained in the sample the level of expression of a plurality of preselected genes; and c. comparing the level of expression of each gene of the plurality of pre-selected genes to a predetermined reference level of expression for each such gene; wherein a higher level of expression of the plurality of pre-selected genes in the sample as compared with the predetermined reference level of expression of such genes indicates that the patient has a reduced risk of reoccurrence of melanoma.
    Type: Application
    Filed: August 2, 2013
    Publication date: August 6, 2015
    Applicant: Icahn School of Medicine at Mount Sinai
    Inventors: Yvonne Saenger, Shanthi Sivendran, Rui Chang, Analisa Difeo